BMO Capital Markets Issues Positive Forecast for Replimune Group (NASDAQ:REPL) Stock Price

Replimune Group (NASDAQ:REPL - Free Report) had its target price increased by BMO Capital Markets from $18.00 to $27.00 in a report published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts have also issued reports about the company. HC Wainwright boosted their target price on Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Wednesday. Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 24th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Replimune Group has a consensus rating of "Buy" and an average price target of $19.14.

Replimune Group Stock Up 9.9 %

Shares of NASDAQ:REPL traded up $1.17 during midday trading on Wednesday, reaching $13.02. The company had a trading volume of 1,465,585 shares, compared to its average volume of 905,541. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The stock has a market cap of $890.83 million, a PE ratio of -4.27 and a beta of 1.28. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The business's 50 day moving average price is $12.18 and its 200 day moving average price is $11.28.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts forecast that Replimune Group will post -2.91 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company's stock.

Institutional Trading of Replimune Group

Several large investors have recently modified their holdings of REPL. Point72 DIFC Ltd acquired a new position in Replimune Group during the second quarter valued at approximately $57,000. Erste Asset Management GmbH acquired a new position in shares of Replimune Group during the 3rd quarter worth $133,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock worth $144,000 after buying an additional 5,926 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after buying an additional 6,748 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Replimune Group in the third quarter valued at about $222,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.